Appclon Obtains Patent Rights for VEGFR2-Binding Antibody Targeting Neovascular Diseases in Europe
[Asia Economy Reporter Minji Lee] Appclon announced on the 20th that it has obtained a patent for an antibody that specifically binds to VEGFR2 in Europe.
Hot Picks Today
"Why Is the Korean Stock Market Surging?"... Even Italy Is Astonished by the KOSPI Rally
- "Invested 95% in Hynix and Reached 10 Billion Won"... Japanese Investor's Proof Post Goes Viral
- "South Korea Shows Similar Trend to Developed Nations"...Obesity Analysis of 232 Million People Worldwide [Reading Science]
- "That Thing Wakes Up Every Night" ... Suspicious Object Covers Rural Village
- "My Wife Is Missing"... Woman in Her 50s Still Unaccounted for Nearly a Month After Climbing Bukhansan Mountain
The company stated, "This concerns a novel VEGFR2 antibody used for the treatment of neovascular-related diseases such as cancer and macular degeneration," and added, "We will utilize the patented material with enhanced value for commercialization through technology transfer."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
